Earnings Feed
Start Free
Home/Filings/4/0000950170-24-106413
4//SEC Filing

Hughes-Wilson Alexandra 4

Accession 0000950170-24-106413

CIK 0001719714other
View on SEC.govCompany Profile

Filed

Sep 12, 8:00 PM ET

Accepted

Sep 13, 4:47 PM ET

Size

14.9 KB

Accession

0000950170-24-106413

Insider Transaction Report

Form 4
Period: 2024-09-11
Mereo BioPharma Group plcMREO
Hughes-Wilson Alexandra
See Remarks
Transactions
  • Exercise/Conversion

    Performance Based Restricted Stock Unit

    2024-09-11−40,000→ 0 total
    Exercise: $0.00From: 2024-09-11Exp: 2025-01-25→ American Depository Shares (40,000 underlying)
  • Exercise/Conversion

    American Depositary Shares representing Ordinary Shares

    2024-09-11+40,000→ 74,548 total
  • Exercise/Conversion

    American Depositary Shares representing Ordinary Shares

    2024-09-11$1.01/sh+75,000$75,750→ 242,881 total
  • Exercise/Conversion

    American Depositary Shares representing Ordinary Shares

    2024-09-11$1.40/sh+93,333$130,666→ 167,881 total
  • Exercise/Conversion

    Share Options (Right to buy)

    2024-09-11$1.40/sh−93,333$130,666→ 0 total
    Exercise: $1.40Exp: 2032-01-14→ American Depository Shares (93,333 underlying)
  • Exercise/Conversion

    Share Options (Right to buy)

    2024-09-11$1.01/sh−75,000$75,750→ 0 total
    Exercise: $1.01Exp: 2033-01-25→ American Depository Shares (75,000 underlying)
Footnotes (4)
  • [F1]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
  • [F2]Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.
  • [F3]160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.
  • [F4]240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.

Documents

1 file

Issuer

Mereo BioPharma Group plc

CIK 0001719714

→
Entity typeother

Related Parties

1
  • filerCIK 0002005875

Filing Metadata

Form type
4
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 4:47 PM ET
Size
14.9 KB
View on SEC.gov